JP2005530735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530735A5 JP2005530735A5 JP2003585723A JP2003585723A JP2005530735A5 JP 2005530735 A5 JP2005530735 A5 JP 2005530735A5 JP 2003585723 A JP2003585723 A JP 2003585723A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2005530735 A5 JP2005530735 A5 JP 2005530735A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- medicament
- warm
- creating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 241001465754 Metazoa Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000005865 ionizing radiation Effects 0.000 claims 3
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0208680A GB0208680D0 (en) | 2002-04-16 | 2002-04-16 | Combination therapy |
| GB0218388A GB0218388D0 (en) | 2002-08-08 | 2002-08-08 | Combination therapy |
| PCT/GB2003/001617 WO2003088971A1 (en) | 2002-04-16 | 2003-04-14 | Combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530735A JP2005530735A (ja) | 2005-10-13 |
| JP2005530735A5 true JP2005530735A5 (enExample) | 2006-05-11 |
Family
ID=29252451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585723A Pending JP2005530735A (ja) | 2002-04-16 | 2003-04-14 | 癌の処置のための併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050215530A1 (enExample) |
| EP (1) | EP1496909B1 (enExample) |
| JP (1) | JP2005530735A (enExample) |
| KR (1) | KR20040103964A (enExample) |
| CN (1) | CN100352441C (enExample) |
| AT (1) | ATE353650T1 (enExample) |
| AU (1) | AU2003216558B2 (enExample) |
| BR (1) | BR0309226A (enExample) |
| CA (1) | CA2482591A1 (enExample) |
| DE (1) | DE60311788T2 (enExample) |
| ES (1) | ES2280735T3 (enExample) |
| IL (1) | IL164564A0 (enExample) |
| MX (1) | MXPA04010166A (enExample) |
| NO (1) | NO20044498L (enExample) |
| NZ (1) | NZ535739A (enExample) |
| WO (1) | WO2003088971A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| BRPI0411567A (pt) * | 2003-06-18 | 2006-08-01 | Angiogene Pharm Ltd | uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente |
| ES2372694T3 (es) * | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| HRP20090495T1 (hr) * | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
| AU2005251722B2 (en) * | 2004-06-03 | 2009-11-12 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| RU2006146612A (ru) | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
| US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
| FR2886151B1 (fr) * | 2005-05-31 | 2007-09-07 | Mayoly Spindler Soc Par Action | Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| EP2283020B8 (en) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
| CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
| JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 副腎皮質癌を治療するためのｏｓｉ−９０６の使用 |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
-
2003
- 2003-04-14 BR BR0309226-7A patent/BR0309226A/pt not_active IP Right Cessation
- 2003-04-14 EP EP03712464A patent/EP1496909B1/en not_active Expired - Lifetime
- 2003-04-14 CA CA002482591A patent/CA2482591A1/en not_active Abandoned
- 2003-04-14 AU AU2003216558A patent/AU2003216558B2/en not_active Ceased
- 2003-04-14 DE DE60311788T patent/DE60311788T2/de not_active Expired - Fee Related
- 2003-04-14 AT AT03712464T patent/ATE353650T1/de not_active IP Right Cessation
- 2003-04-14 CN CNB03813702XA patent/CN100352441C/zh not_active Expired - Fee Related
- 2003-04-14 JP JP2003585723A patent/JP2005530735A/ja active Pending
- 2003-04-14 ES ES03712464T patent/ES2280735T3/es not_active Expired - Lifetime
- 2003-04-14 NZ NZ535739A patent/NZ535739A/en unknown
- 2003-04-14 KR KR10-2004-7016666A patent/KR20040103964A/ko not_active Ceased
- 2003-04-14 WO PCT/GB2003/001617 patent/WO2003088971A1/en not_active Ceased
- 2003-04-14 US US10/511,744 patent/US20050215530A1/en not_active Abandoned
- 2003-04-14 MX MXPA04010166A patent/MXPA04010166A/es active IP Right Grant
-
2004
- 2004-10-13 IL IL16456404A patent/IL164564A0/xx unknown
- 2004-10-21 NO NO20044498A patent/NO20044498L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006504723A5 (enExample) | ||
| JP2005511597A5 (enExample) | ||
| IL171683A (en) | Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment | |
| JP2006500346A5 (enExample) | ||
| IL184051A (en) | Acetylated GLP-1 compounds, containing and using pharmaceutical preparations | |
| IL213597A0 (en) | Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
| IL178822A (en) | 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders | |
| IL165532A (en) | History of Aryl Carbonyl, Pharmaceutical Preparations Containing Them and Their Use in the Preparation of Medicines for the Treatment of Metabolic Disorders | |
| IL231576A (en) | Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| IL164373A (en) | Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer | |
| IL179714A (en) | Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation | |
| CL2003002287A1 (es) | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS | |
| IL201176A (en) | 4-amino-1-h-pyrazolo [3,4- d] pyrimidine-3-ram-phenyl, a pharmaceutical containing them and their use in the preparation of a drug | |
| JP2012524089A5 (enExample) | ||
| WO2006050155A3 (en) | Cancer therapeutic compositions | |
| WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
| JP2008514577A5 (enExample) | ||
| DE69215999D1 (de) | Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs | |
| JP2015507020A5 (enExample) | ||
| IL187575A (en) | Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| IL179075A (en) | Use of random copolymer preparations in the preparation of drugs for the treatment of diseases, the reduction of undesirable immune reactions and the treatment of multiple sclerosis and pharmaceutical preparations containing random copolymer preparations | |
| IL178939A (en) | Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer |